Laparoscopic radical prostatectomy (LRP) is an established treatment option for patients with prostate cancer in selected centres with appropriate expertise. The goal of LRP is to achieve excellent cancer control whilst attempting to preserve normal urinary continence and erectile function. We studied our single-centre experience evaluating the oncological outcomes in patients undergoing LRP.
Patients and methods
Three hundred and six patients underwent LRP between 2005 and 2011. Patients were divided into D'Amico low-, intermediate- and high-risk groups.
Results
The mean age was 61.9 years (range 46-74 years). The two most important factors predictive of positive surgical margins (PSMs) at LRP were the initial prostate-specific antigen (PSA) level and tumour stage at diagnosis. The overall PSM rate was 26.7%. For low D'Amico-risk patients, the PSM was 24.5%, intermediate-risk patients had a PSM of 32.4%, while high-risk patients had a PSM of 13.6%; 6.4% (nine of 139) of patients sampled had evidence of lymph node-positive disease. Five-year PSA progression-free survival rates were 83% in low-risk patients, 57% in intermediate-risk and 41% in high-risk patients.
Conclusion
LRP offers good oncological outcomes in the low- and intermediate-risk groups with low incidence of biochemical recurrence for patients with localised disease. Our high-risk group has a low incidence of PSM and a five-year PSA progression-free survival rate of 41%. Patients with high-risk, but non-metastatic, prostate cancer can be offered a minimally invasive prostatectomy in an experienced centre.
Office for National Statistics.Cancer statistics registrations. Registrations of cancer diagnosed in 2009. http://www.ons.gov.uk/.
2.
MoketeM, ShackleyDC, BettsCD.The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.BJU Int2006; 97; 266–269.
3.
CrawfordED.Understanding the epidemiology, natural history and key pathways involved in prostate cancer -Urology.2009 May;73(5 Suppl): S4–10
4.
VasdevN, Kass-IliyyaA, PatelA.Developing a laparoscopic radical prostatectomy service: Defining the learning curve.J Endourol2012; 26: 903–910.
5.
HanM, PartinAW, PoundCR.Long term biochemical disease-free and cancer-specific survival following anatomic retropubic radical prostatectomy. The 15-year John Hopkins experience.Urol Clin North Am2001; 28: 555–565.
6.
GuillanneauB, and VallancienGl. Laparoscopic radical prostatectomy: The Montsouris technique.J Urol2000; 163: 1643–1649.
7.
PoundCR, PartinAW, EpsteinJI.Prostate-specific antigen after anatomic retropubic radical prostatectomy. Patterns of recurrence and cancer control.Urol Clin North Am1997; 24: 395–406.
8.
HussainS, GunnellD, DonovanJ.Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004.BJU Int2008; 101: 547–555.
9.
HanchanaleVS, McCabeJE, and Javle. Radical prostatectomy practice in England.Urol J2010; 7: 243–248.
10.
BiancoFJJr, ScardinoPT, and EasthamJA.Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function (“trifecta”).Urology2005; 66 (5 Suppl): 83–94.
HullGW, RabbaniF, AbbasF.Cancer control with radical prostatectomy alone in 1,000 consecutive patients.J Urol2002; 167 (2 Pt 1): 528–534.
13.
WalzJ, JoniauS, ChunFK.Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy.BJU Int2011; 107: 765–770.
14.
D'AmicoAV, WhittingtonR, MalkowiczSB.Biochemical outcome after radical prostatectomy, external beam radiotherapy or interstitial radiation therapy for clinically localized prostate cancer.JAMA1998; 280: 969–974.
15.
D'AmicoAV, CoteK, LoffredoM.Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer.J Clin Oncol2002; 20: 4567–4573.
16.
BuschJ, StephanC, HeroldA.Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: A single-centre experience.BJU Int2012; 110 (11 Pt C): E985–E990.
17.
TouijerK, SecinFP, CroninAM.Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience.Eur Urol2009; 55: 1014–1019.
18.
SpahnM, JoniauS, GonteroP.Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: A European multi-institutional study of 712 patients.Eur Urol2010; 58: 1–7, discussion 10-11.
19.
PloussardG, SalomonL, AlloryY.Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.BJU Int2010; 106: 86–90.
20.
CroninAM, GodoyG, and VickersAJ.Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates.J Urol2010; 183: 984–989.
21.
BerglundRK, JonesJS, UlchakerJC.Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: A prospective analysis.Urology2006; 67: 1253–1256.
22.
KupelianP, KatcherJ, LevinH.External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.Cancer J Sci Am1997; 3: 78–87.
BoorjianSA, ThompsonRH, SiddiquiS.Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.J Urol2007; 178 (3 Pt 1): 864–870, discussion 870-871.
25.
JoslynSA, and KonetyBR.Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer.Urology2006; 68: 121–125.
26.
MiyakeH, HaraI, KurahashiT.Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR.Clin Cancer Res2007; 13: 1192–1197.
27.
SerniS, MasieriL, MinerviniA.Cancer progression after anterograde radical prostatectomy for pathologic Gleason score 8 to 10 and influence of concomitant variables.Urology2006; 67: 373–378.
28.
MessingEM, ManolaJ, YaoJ.Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.Lancet Oncol2006; 7: 472–479.
29.
BaderP, BurkhardFC, MarkwalderR.Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?J Urol2003; 169: 849–854.
30.
ThompsonIMJr, TangenCM, ParadeloJ.Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial.JAMA2006; 296: 2329–2335.
31.
BollaM, van PoppelH, ColletteL.Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911).Lancet2005; 366: 572–578.
32.
MessingEM, ManolaJ, SarosdyM.Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.N Engl J Med1999; 341: 1781–1788.
33.
HugginsC, StevensREJr, and HodgesCV.The effect of castration on advanced carcinoma of the prostate gland.Arch Surg1941; 43: 209.
34.
DorffTB, FlaigTW, TangenCM.Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.J Clin Oncol2011; 29: 2040–2045.
35.
ByarDP.Treatment of prostatic cancer: Studies by the Veterans Administration cooperative urological research group.Bull N Y Acad Med1972; 48: 751–766.
36.
RADICALS (Radiotherapy and androgen deprivation in combination after local surgery) - A randomised controlled trial in prostate cancer, http://www.radicals-trial.org/ (2013, accessed 17 September 2012).
